Abstract 402P
Background
Cancer survivors have been reported to face challenges as they return to work after completing antineoplastic treatment. In order to understand the burden of return-to-work challenges among cancer survivors in Singapore, we aim to describe the work-related outcomes, including employment rates, absenteeism and presenteeism, among local cancer survivors.
Methods
This was a cross-sectional study conducted at the National Cancer Centre Singapore in 2018. Breast cancer, colorectal cancer and lymphoma survivors who were in disease remission and have completed treatment for at least 6 months were recruited. Employment history and absenteeism data in the past 6 months were collected using self-administered questionnaires. Presenteeism was self-reported using the Work Limitations Questionnaire.
Results
A total of 501 patients were recruited. Most participants were Chinese (79.6%), followed by Malay (11.8%), Indian (4.6%) and other ethnicities (4.0%). Over half were breast cancer survivors (69.5%), followed by colorectal cancer (15.5%) and lymphoma (15.0%) survivors. The median age of the participants was 55.7 years (IQR: 50.1 to 60.5 years) while the median time after primary treatment completion was 3.7 years (IQR: 1.9 to 6.1 years). The majority of cancer survivors were employed with most participants reporting working full-time (47.5%), followed by part-time workers (10.2%) and self-employed individuals (5.8%). Out of the survivors who did not have paid employment, a substantial proportion (24.3%) were unemployed due to health-related reasons. Among employed participants, 56.9% reported taking time off work due to ill health or to see a physician in the past 6 months. The median absenteeism rate reported among working survivors was 0.8% of working time (range: 0 to 73.1%) while the median presenteeism or productivity loss at work due to health-related problems was reported to be 1.2% (range: 0 to 20.3%).
Conclusions
A significant proportion of cancer survivors in Singapore require time off from work or leave employment due to health-related issues. Further studies should be conducted to identify survivors who are at high risk for return-to-work challenges and should be offered occupational rehabilitation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Singapore Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract